GMGabriella Morozzi

Gabriella Morozzi

*This is an algorithmically generated author record based on publicly available information.

Gabriella Morozzi has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Mauro Galeazzi

    Sezione di Reumatologia, Dipartimento di Medicina Clinica e Scienze Immunologiche, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy

    6 shared publications
  • Antonella Simpatico

    Rheumatology Unit, Department of Clinical Medicine and Immunological Sciences, Policlinico Universitario “S. Maria alle Scotte”, Siena, Italy

    3 shared publications
  • Francesca Bellisai

    Sezione di Reumatologia, Dipartimento di Medicina Clinica e Scienze Immunologiche, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy

    3 shared publications
  • Marilina Tampoia

    Laboratorio di Patologia Clinica, Azienda Ospedaliera Universitaria, Policlinico di Bari, Bari, Italy

    3 shared publications
  • Roberto Marcolongo

    3 shared publications
  • Clodoveo Ferri

    2 shared publications

Latest Publications

  • Open Access

    Serological epitope profile of anti-Ro52–positive patients with systemic autoimmune rheumatic diseases

    by Maria Infantino, Francesca Meacci, Valentina Grossi, Maurizio Benucci, Gabriella Morozzi, Elio Tonutti, Marilina Tampoia, Antonina Ott, Wolfgang Meyer, Fabiola Atzeni, et al.

    Ro52 is an interferon-inducible protein of the tripartite motif family. Antibodies against Ro52 have been described in patients with different autoimmune diseases, such as systemic lupus erythematosus and Sjögren’s syndrome, that are often associated with anti-Ro60 antibodies. The Ro52 autoantigen is extraordinarily immunogenic, and its autoantibodies are directed against both linear and conformational epitopes. The aim of this study was to evaluate the prevalence of antibodies to the five Ro52 domains, as well as to Ro52 176– to 196–amino acid (aa) and 200–239-aa peptides, in different systemic autoimmune rheumatic diseases (SARDs). We also aimed to verify whether antibodies to a single domain or domain association could increase their diagnostic specificity for any SARD. Serum samples were obtained from 100 anti-Ro52 antibody–positive patients with SARDs and from 68 controls (50 healthy donors and 18 patients with other autoimmune or allergic diseases). A special line immunoassay was created containing a full-length Ro52 antigen expressed in insect cells using the baculovirus system, five recombinant Ro52 antigen fragments [Ro52-1, Ro52-2, Ro52-3, Ro52-4 (partly overlapping Ro52-1 and Ro52-2), and Ro52-5 (partly overlapping Ro52-2 and Ro52-3)], and two Ro52 peptides (176–196 aa and 200–239 aa), all expressed in Escherichia coli. In patients with SARDs, fragment prevalence rates were as follows: Ro52-1 = 3 %, Ro52-2 = 97 %, Ro52-3 = 0 %, Ro52-4 = 9 %, Ro52-5 = 28 %, Ro52 175–196-aa peptide = 6 %, and Ro52 200–239-aa peptide = 74 %. All control samples were negative for the full-length Ro52 and for the five fragments tested. The main epitope of the Ro52 antigen was localized on fragment 2 (aa 125–267), and the majority (97 %) of SARD sera had antibodies that target this fragment. As most of the samples were positive for fragment 2 and only some for fragments 4 or 5, which partially overlap fragment 2, it seems that the target epitope is localized in the middle of fragment 2 or in the area between fragments 4 and 5. No antibody against a single epitope or a combination of epitopes was linked to any of the single SARDs.


  • Rheumatoid factor isotypes in patients with erosive osteoarthritis of the hand

    by Giacomo M. Guidelli, Gabriella Morozzi, Antonella Simpatico, Antonella Fioravanti


  • Open Access

    Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients

    by Gabriella Morozzi, Francesca Bellisai, Irene Fineschi, Francesca Scaccia, Gabriella Pucci, Antonella Simpatico, Marilina Tampoia, Alessandra Chialà, Giovanni Lapadula, Mauro Galeazzi

    The aim of our study was to determine the prevalence, clinical significance of antibodies to individual histone components and to evaluate their correlation with other autoantibody specificities in a cohort of Italian SSc patients. Some authors, demonstrated high prevalence of anti-histone antibodies in Italian SSc patients, associated with cardiac and renal involvement, suggesting a prognostic value of these autoantibodies; however, these data need to be confirmed. Serum from 112 adult SSc patients, classified as diffuse (dc) and limited cutaneous (lc) SSc subsets were analyzed for autoantibodies by indirect immunofluorescence, fluoroenzyme immunoassay and enzyme immunoassay. AHA were found in 13 patients (11.6%), nine with lcSSc and four with dcSSc. Among them, five patients were anti-Scl70+ and four were anti-CENP B+. The presence of AHA was not associated with multi-organ involvement or with diffuse subset, as already described. Anti-Scl70 was detected in 43% of patients, anti-CENP B in 32% and anti-RNA polymerase III in 7.1%. We confirmed the association between anti-Scl70 antibodies and pulmonary fibrosis (OR 15.75, p < 0.0001). In our experience, the very low prevalence of AHA in Italian SSc patients and the lack of association with clinical manifestations suggest that this test is of little clinical use; however, it would be worthwhile extending the study to a larger population of patients.


    • 23 February 2011
      • Vol. 29  (1) , 50-6

    Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study.

    by Anna Ghirardello, Danilo Villalta, Gabriella Morozzi, Antonella Afeltra, Mauro Galeazzi, Roberto Gerli, Alessandro Mathieu, Pier Luigi Meroni, Francesca Pregnolato, Paola Migliorini, et al.

    An Italian multicentre study was promoted in order to assess the accuracy of four anti-double-stranded DNA (dsDNA) antibody assays for SLE diagnosis and monitoring. Two hundred and twenty-three patients with established SLE according to ACR classification criteria were enrolled from 9 centres. They included 59 patients at first evaluation (disease duration <12 months) and 164 with longer disease duration (median disease duration 120 months). The sera from 55 healthy subjects and 161 patients with rheumatic, infectious or neoplastic diseases were tested as controls. SLE activity was measured by ECLAM score. Anti-dsDNA antibodies were detected in serum by means of FarrzymeTM assay, fluoroenzymeimmunoassay (EliATM), Crithidia luciliae indirect immunofluorescence (CLIFT) or Farr radioimmunoassay (Farr). Cut-off values of quantitative assays were chosen by ROC curves analysis. Statistics were conducted by SPSS software package. Sensitivity for SLE diagnosis ranged between 66% with Farrzyme to 95% with Farr, with about 90% specificity for all the methods tested. Farrzyme assay was more specific than the others towards patients with non-SLE connective tissue disease. The four methods were moderately concordant and correlated among them, all showing a positive association with active disease, renal or haematologic involvement, and a negative association with central nervous system disease. Whatever the assay used, anti-dsDNA antibody levels correlated with disease activity with r correlation coefficients ranging from 0.336 to 0.425 (p<0.0001). The diagnostic accuracy for SLE of evaluated anti-dsDNA antibody assays is comparable and potentially improvabile especially in terms of specificity. The clinical adherence of the assays confirms the value of anti-dsDNA antibody for SLE monitoring.


  • Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis

    by Danilo Villalta, Gabriella Morozzi, Marilina Tampoia, Claudia Alpini, Ignazio Brusca, Valeria Salgarolo, Wolfgang Papisch, Nicola Bizzaro


  • Anti-Cofactor Autoantibodies in Systemic Lupus Erythematosus: Prevalence, Clinical and HLA Class II Associations

    by Gian Domenico Sebastiani, Gabriella Morozzi, Francesca Bellisai, Irene Fineschi, Maria Romana Bacarelli, Antonella Simpatico, Josep Font, Ricard Cervera, Frederic Houssiau, Antonio Fernandez-Nebro, et al.

    The aim of our study was to evaluate the clinical and HLA-class II allele associations of some anti-cofactor antibodies in a homogeneous group of European patients with SLE. One hundred thirty-six patients with SLE, fulfilling four or more of the ACR 1997 revised criteria for the classification of the disease, coming from 7 European countries, were enrolled consecutively. Anti-prothrombin (anti-PT), anti-annexin V (anti-AnnV), anti-protein C (anti-Cprot) and anti-protein S (anti-Sprot) were determined by using commercial ELISA kits. Molecular typing of HLA-DRB1, DRB3, DRB4, DRB5, DQA1, DQB1 and DPB1 loci was performed by using PCR-SSOP method, carried out using digoxygenin (DIG) labeled probes. The prevalence of anti-AnnV, anti-PT, anti-Cprot and anti-Sprot was 19%, 10.4%, 4.4% and 8.1%, respectively. Twenty-seven % of anti-AnnV positive patients reported migraine vs 5.5% of anti-AnnV negatives (p = 0.003, but p not significant, odds ratio (OR) = 6.4, 95% confidence interval (CI) = 2–21). Anti-PT, anti-AnnV and anti-Sprot were positively associated with some HLA alleles, but pc was not significant. In this study we have shown that some HLA alleles carry the risk to produce antibodies against phospholipid-binding proteins, but these association need confirmation in other studies, because they have never been reported and appear to be weak associations.


  • Cartilage Oligomeric Matrix Protein Level in Rheumatic Diseases

    by Gabriella Morozzi, Marta Fabbroni, Francesca Bellisai, Gabriella Pucci, Mauro Galeazzi

    Cartilage oligomeric matrix protein (COMP) is a tissue‐specific noncollagenous protein that was first detected in the serum and the synovial fluid of patients suffering from rheumatic disorders, such as rheumatoid arthritis, reactive arthritis, juvenile chronic arthritis, and osteoarthritis. In this review, the authors consider serum COMP levels in different diseases and discuss their study of patients with rheumatoid arthritis treated with anti‐TNF‐α, to evaluate whether COMP is able to predict a rapid and sustained clinical response to these drugs. They observe that patients with high COMP levels have a lower ACR 70 response independently of the state of systemic inflammation, and conclude that COMP seems to have a pathogenetic role that is independent of the mechanisms regulating inflammatory processes.


  • Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis

    by G. Morozzi, M. Fabbroni, F. Bellisai, S. Cucini, A. Simpatico, M. Galeazzi

    The aim of this study was to evaluate serum biomarkers, used in clinical routine, to predict the American College of Rheumatology (ACR) response to long-term anti-TNF alpha treatment (adalimumab). Sera from 29 consecutive rheumatoid arthritis patients were analysed for anti-cyclic citrullinated peptide (anti-CCP), cartilage oligomeric matrix protein (COMP) and IgM and IgA RFs (class-specific rheumatoid factors) at the start of treatment with adalimumab and after 3, 6 and 12 months. The response to the therapy was evaluated by ACR 20, 50, 70 and by DAS 28 scores. The mean serum COMP level of the population did not change after treatment. However, patients with low serum COMP levels (p < 0.02) higher ACR70 response (>50%) within 3 months, and also at 6 months, than patients with higher COMP values (ACR70 < 20%). This was also reflected by significantly higher decrease in DAS score at 3 (p < 0.02) and 6 months (p < 0.01) treatments. The IgM RF titre decreased significantly (p = 0.02) after the therapy, but the percentage of serum positivity for anti-CCP and IgA/IgM RF did not change. No significant correlation was shown between serum COMP levels and C-reactive protein/erythrocyte sedimentation rate during the follow-up. Neither were any correlations shown between ACR/DAS 28 scores and anti-CCP, Ig M/IgA RFs. Our data indicate that low (<10 U/l) serum COMP before starting anti-TNF alpha treatment predicts a rapid (within 3 months) and high ACR70 response compared to RA patients with higher COMP values. This might reflect different mechanisms in the cartilage process in the RA disease at that time of treatment with different therapeutic sensitivity to anti-TNF alpha treatment.


  • Open Access

    Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: further serological evidence of the disease as a subset of osteoarthritis

    by G Morozzi, F Bellisai, A Fioravanti, M Galeazzi

    The relationship between EOA and classical OA is controversial, as some authors consider it to be a separate disease entity, some regard it as one end of the spectrum of OA, and some regard it as an interface between OA and RA.1, 4 A relationship between EOA and RA was first suggested by Ehrlich,5 who noted the superimposition of clinical, laboratory, and imaging findings of RA in 62 of 170 patients initially diagnosed with EOA. Moreover, in the early stages of the disease, the differential diagnosis between EOA and other arthritis, such as RA or psoriatic arthritis, may pose a challenge, requiring a number of laboratory tests and investigations.3, 6– 8 It is well known that anti-cyclic citrullinated peptide antibodies (anti-CCP) are highly specific for RA and good predictors of radiographic joint damage9; for that reason this study aimed at detecting these autoantibodies in serum samples of patients with EOA, in order to ascertain their clinical usefulness and, possibly, to contribute to the clarification of the relationship of EOA with classical OA and RA. On the one hand, positive results may support the hypothesis that EOA is an interface between OA and RA, but, on the other hand, negative results may support the hypothesis that EOA is one end of the spectrum of OA.


    • 11 September 2004
      • Vol. 14  (5) , 327-31

    Chromosome aberrations in Raynaud's phenomenon.

    by Giovanni Porciello, Roberto Scarpato, Franca Storino, Lucia Migliore, Clodoveo Ferri, Francesca Cagetti, Gabriella Morozzi, Francesca Bellisai, Roberto Marcolongo, Mauro Galeazzi

    We evaluated the occurrence of spontaneous chromosome damage in cultured peripheral lymphocytes of subjects with idiopathic and pre-scleroderma Raynaud's phenomenon, by means of molecular cytogenetic analysis. Using the micronucleus assay as a marker of chromosome alteration, we studied 30 patients with pre-scleroderma Raynaud's phenomenon, 30 patients with idiopathic Raynaud's phenomenon and 30 healthy subjects. All subjects were classified as ANA-, ACA+ or Scl 70+. To identify the mechanism of micronucleus formation, fluorescence in situ hybridisation analysis was also performed. Pre-scleroderma Raynaud's phenomenon subjects showed significantly higher micronucleus frequencies than idiopathic Raynaud's phenomenon subjects and controls (37.0 +/- 11.5 vs. 11.1 +/- 3.2 and 10.7 +/- 2.7 respectively p < 0.0001). Interestingly, subjects with idiopathic Raynaud's phenomenon displayed micronucleus frequency comparable to that of healthy controls. Furthermore, ACA+ subjects showed the highest micronucleus frequencies (41.0 +/- 7.6) as compared to subjects with Scl 70+ antibody (25.0 +/- 3.5). Our results show that circulating lymphocytes of only pre-scleroderma Raynaud's phenomenon subjects undergo chromosomal damage, as detected by the micronucleus assay, at a higher rate than expected. No prevalence of aneuploidogenic or clastogenic events in micronucleus formation is revealed by fluorescence in situ hybridisation analysis.